A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer's Disease

The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are:
* Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13?
* Does buntanetap/Posiphen improve function as measured by ADCS-iADL?
* What medical issues do participants have, if any, when taking buntanetap/Posiphen?
Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease.
Participants will:
* Take buntanetap/Posiphen or a placebo every day for 18 months
* Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18
* Complete pre- and post-clinic visit phone calls

开始日期2025-02-04

申办/合作机构

Annovis Bio, Inc.

[+1]

NCT05686044

/ Completed临床2/3期

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants With Mild to Moderate Alzheimer's Disease

The purpose of this study is to measure efficacy and safety of three different doses of buntanetap/Posiphen compared with placebo in participants with mild to moderate Alzheimer's disease.
Study details include:
The double-blind treatment duration will include a screening period of up to 42 days followed by 12 weeks of treatment at home.
The study duration will be 4-5 months. There will be 4 in-clinic visits and 1 phone call.

开始日期2023-04-01

申办/合作机构

Annovis Bio, Inc.

NCT05357989

/ Completed临床3期

A 6-month Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial Investigating the Efficacy, Safety, and Tolerability of Two Different Doses of Buntanetap or Placebo in Patients With Early Parkinson's Disease

The purpose of this study is to measure safety and efficacy of buntanetap/posiphen capsules compared with placebo capsules in participants with early PD.
Study details include:
* The study duration will be up to 7-8 months.
* The double-blind treatment duration will be up to 6 months.
* There will be 5 in-clinic visits and 7 phone calls

开始日期2022-08-03

申办/合作机构

Annovis Bio, Inc.

[+1]

100 项与 Buntanetap 相关的临床结果

登录后查看更多信息

100 项与 Buntanetap 相关的转化医学

登录后查看更多信息

100 项与 Buntanetap 相关的专利（医药）

登录后查看更多信息

项与 Buntanetap 相关的文献（医药）

2024-04-01·SLAS discovery : advancing life sciences R & D

Real-time thiol detection in iPSC-derived neuron cultures using SemKur-IM, a novel fluorescent dithio probe

Article

作者: Alvarez, Roxanne ; Sem, Daniel S ; Kurfis, Jayson ; Hendrickson, Michael

Neurological disorders associated with inflammation and oxidative stress show reduced glutathione (GSH) levels in the human brain. Drug discovery efforts and pharmacological studies would benefit from tools (e.g. chemical probes) that detect changes to oxidative stress, from the perspective of physiologically-relevant reporters like cellular thiols, including GSH. To this end, we have developed a fluorescence visualization assay using iPSC-derived cortical glutamatergic neurons that were loaded with 25 μM of a novel thiol-detection fluorescent probe, SemKur-IM. This probe enables visualization of cellular thiol level changes in the neuronal somas and neurites, in response exposure to N-acetyl-cysteine (NAC). Cellular thiol redox state was observed to change, based on an increase in green fluorescence (485 nm excitation maximum; 525 nm emission maximum) due to changes in thiol levels, from 0 to 40 mM. Interestingly, prior to treatment with NAC, cells did not appear to have significant levels of reduced thiols. Our studies demonstrate the utility of SemKur-IM in the detection of thiol levels in live cells in response to chemical exposures, such as from drugs that return the cell to a healthier reduced state. An initial application to screening the effects of an Alzheimer's disease drug candidate, Posiphen, using fluorescence cell sorting is presented. Other potential applications include high throughput screening of central nervous system (CNS) drugs thought to work by affecting cellular redox state in neurons.

2023-01-01·The journal of prevention of Alzheimer's disease

Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients

Article

作者: Cheng Fang ; K. Liow ; M. Maccecchini ; P. Hernandez ; E. Damiano ; H. Zetterberg ; D. Feng ; K. Blennow ; M. Chen

BACKGROUND:

Previously we reported the clinical safety and pharmacological activity of buntanetap (known as Posiphen or ANVS401) in healthy volunteers and mild cognitive impaired (MCI) patients (21). The data supported continued clinical evaluation of buntanetap for treating Alzheimer's Disease (AD). Neurodegenerative diseases such as AD and Parkinson's disease (PD) share several pathological manifestations, including increased levels of multiple neurotoxic protein aggregates. Therefore, a treatment strategy that targets toxic species common to both disorders can potentially provide better clinical outcomes than attacking one neurotoxic protein alone. To test this hypothesis, we recently completed a clinical study in early AD and early PD participants and report the data here.

OBJECTIVES:

We evaluated safety, pharmacokinetics, biomarkers, and efficacy of buntanetap in treating early AD and PD patients.

DESIGN:

Double-blind, placebo-controlled, multi-center study.

SETTING:

13 sites in the US participated in this clinical trial. The registration number is NCT04524351 at ClinicalTrials.gov.

PARTICIPANTS:

14 early AD patients and 54 early PD patients.

INTERVENTION:

AD patients were given either 80mg buntanetap or placebo QD. PD patients were given 5mg, 10mg, 20mg, 40mg, 80mg buntanetap or placebo QD.

MEASUREMENTS:

Primary endpoint is safety and tolerability; secondary endpoint is pharmacokinetics of buntanetap in plasma; exploratory endpoints are 1) biomarkers in cerebrospinal fluid (CSF) in both AD and PD patients 2) psychometric tests specific for AD (ADAS-Cogs and WAIS coding test) or PD (MDS-UPDRS and WAIS coding test).

RESULTS:

Buntanetap was safe and well tolerated. Biomarker data indicated a trend in lowering levels of neurotoxic proteins and inflammatory factors and improving axonal integrity and synaptic function in both AD and PD cohorts. Psychometric tests showed statistically significant improvements in ADAS-Cog11 and WAIS coding in AD patients and MDS-UPDRS and WAIS coding in PD patients.

CONCLUSIONS:

Buntanetap is well tolerated and safe at doses up to 80mg QD in both AD and PD patients. Cmax and AUC increase with dose without evidence for a plateau up to 80mg QD. The drug shows promising evidence in exploratory biomarker and efficacy measures. Further evaluation of buntanetap in larger, longer-term clinical trials for the treatment of AD and PD are warranted.

2022-02-11·ACS pharmacology & translational science

In Silico and Ex Vivo Analyses of the Inhibitory Action of the Alzheimer Drug Posiphen and Primary Metabolites with Human Acetyl- and Butyrylcholinesterase Enzymes

Article

作者: Furqan, Tiyyaba ; Tweedie, David ; Greig, Nigel H. ; Hasan Mahmood, Muhammad Sibte ; Kamal, Mohammad A. ; Batool, Sidra

Alzheimer's disease (AD) is the most common neurodegenerative disorder worldwide. Ongoing research to develop AD treatments has characterized multiple drug targets including the cholinergic system, amyloid-β peptide, phosphorylated tau, and neuroinflammation. These systems have the potential to interact to either drive or slow AD progression. Promising agents that simultaneously impact many of these drug targets are the AD experimental drug Posiphen and its enantiomer phenserine that, currently, are separately being evaluated in clinical trials. To define the cholinergic component of these agents, the anticholinesterase activities of a ligand dataset comprising Posiphen and primary metabolites ((+)-N1-norPosiphen, (+)-N8-norPosiphen, and (+)-N1,N8-bisnorPosiphen) were characterized and compared to those of the enantiomer phenserine. The "target" dataset involved the human cholinesterase enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Binding interactions between the ligands and targets were analyzed using Autodock 4.2. The computationally determined inhibitory action of these ligands was then compared to ex vivo laboratory-measured values versus human AChE and BChE. While Posiphen lacked AChE inhibitory action, its major and minor metabolites (+)-N1-norPosiphen and (+)-N1,N8-bisnorPosiphen, respectively, possessed modest AChE inhibitory activity, and Posiphen and all metabolites lacked BChE action. Phenserine, as a positive control, demonstrated AChE-selective inhibitory action. In light of AChE inhibitory action deriving from a major and minor Posiphen metabolite, current Posiphen clinical trials in AD and related disorders should additionally evaluate AChE inhibition; particularly if Posiphen should be combined with a known anticholinesterase, since this drug class is clinically approved and the standard of care for AD subjects, and excessive AChE inhibition may impact drug tolerability.

140

项与 Buntanetap 相关的新闻（医药）

2025-12-03

·GlobeNewswire-Health Care

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG), taking place December 4-6, 2025 in San Diego, California. The presentation builds on momentum from the Company’s recent Phase 3 PD biomarker data, showing that patients with amyloid co-pathology experience more pronounced cognitive decline, which is counteracted and reversed by buntanetap. In the same patients, buntanetap also reduces tau biomarkers, which are known to increase with disease severity. The presentation will also debut a cross-study comparison of the completed trials, providing the most comprehensive look yet at cognitive outcomes across all tested indications by Annovis and highlighting the population that benefits most – patients with amyloid pathology. In both Parkinson’s and Alzheimer’s, individuals with biomarker-confirmed presence of amyloid experience the greatest cognitive gain following buntanetap. These findings further validate the drug’s mechanism as a translational inhibitor of neurotoxic aggregating proteins and support the Company’s next strategic steps. Presentation details: Title: Amyloid co-pathology, cognitive decline, and improvement in buntanetap-treated Parkinson’s disease dementia patientsPresenter: Maria Maccecchini, Ph.D., President and CEOFormat: Poster guided tourTime of presentation: December 5, 6:15 p.m. PST The data presented at the meeting will be posted on the Company's website following the conference. The PSG Annual Meeting brings together leading investigators, coordinators, trainees, advocates, and allied stakeholders to advance collaborative research and showcase the latest advances and best practices in PD. About AnnovisHeadquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X. Investor AlertsInterested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts. Forward-Looking StatementsThis press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law. Contact Information:Annovis Bio Inc.101 Lindenwood DriveSuite 225Malvern, PA 19355www.annovisbio.com Investor Contact:Alexander Morin, Ph.D.Director, Strategic CommunicationsAnnovis Bioir@annovisbio.com‍

临床3期

2025-11-24

·GlobeNewswire-Health Care

Annovis Announces Two Presentations at the CTAD 2025 Conference

MALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced two presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place December 1-4, 2025 in San Diego, California. The presentations will highlight progress across the Alzheimer’s and Parkinson’s programs, with a particular focus on recent biomarker data supporting the potential disease-modifying activity of buntanetap. Details: Presentation #1 (P073) Title: Amyloid co-pathology and cognitive decline in buntanetap-treated Parkinson’s disease dementia patientsPresenter: Cheng Fang, Ph.D., Senior VP, Research & DevelopmentTime: December 1, 3:00 pm – December 2, 5:30 pm Presentation #2 (P007) Title: Double 6/18-month Phase 3 study to reproduce symptomatic and potentially show disease-modifying efficacy of buntanetap in treating Alzheimer’s diseasePresenter: Maria Maccecchini, Ph.D., President and CEOTime: December 1, 3:00 pm – December 2, 5:30 pm “We look forward to attending CTAD, which comes at the perfect moment to share our latest findings on biomarkers and cognition with the scientific community—work we believe will resonate with clinicians, researchers, and industry leaders,” said Maria Maccecchini, Ph.D., President and CEO of Annovis. “Across both disease indications, our biomarker data tell a clear story—buntanetap has the potential to address the root drivers of cognitive decline. These results not only confirm the efficacy of buntanetap seen in our earlier studies but also give us a clearer path forward as we work to bring an effective treatment to patients who urgently need better options.” About AnnovisHeadquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X. Investor AlertsInterested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts. Forward-Looking StatementsThis press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law. Contact Information:Annovis Bio Inc.101 Lindenwood DriveSuite 225Malvern, PA 19355www.annovisbio.com Investor Contact:Alexander Morin, Ph.D.Director, Strategic CommunicationsAnnovis Bioir@annovisbio.com‍

临床3期

2025-11-23

·钟书神经药研所

MJFF：报告2025年帕金森病研发管线八大创新方向

点击上方蓝字关注“钟书神经药研所” 迈克尔·J·福克斯帕金森病研究基金会（MJFF）是全球领先的帕金森病研究组织，其使命是加速开发下一代帕金森病（PD）疗法，并最终寻求治愈方法。在一份《帕金森病重点治疗临床研发管线报告》中，来自MJFF的临床研发人员全面概述了当前帕金森病治疗领域的研发动态。 2025帕金森病整体研发管线概览自20世纪50-60年代左旋多巴及其他主要靶向多巴胺疗法获批上市以来，工业界不断推出日益多样化的治疗手段。许多疗法仍聚焦于多巴胺能系统，以解决疾病晚期核心的运动障碍。部分疗法则靶向其他脑内神经递质系统，有望改善帕金森病的非运动症状及其他并发症。深部脑刺激（DBS）和聚焦超声消融等外科神经调控技术的进展，也为应对运动挑战提供了更多选择。然而，目前尚无已获批疗法证实能够延缓或阻止帕金森病的病理进程及其导致的进行性残疾，这仍是当前治疗研发管线的关键目标。该份报告共追踪了截至2025年4月178种处于临床开发阶段的帕金森病疗法。其中疾病修饰疗法占主导（约占51%），该类疗法旨在延缓或阻止疾病进展。其次为针对PD患者运动症状管理的疗法，占34%；针对非运动症状与并发症管理的疗法占15%。目前处于临床阶段的疗法针对了多种广泛的PD病理生理学相关通路，反映了对PD复杂病理理解的深化。主要靶点包括： α-突触核蛋白 LRRK2 GBA1 炎症/免疫系统线粒体与代谢应激多巴胺及其他神经递质系统细胞替代疗法在研疗法中，小分子药物仍是主流（66%），但给药方式不断创新（例如采用皮下泵形式进行给药）；新型疗法如细胞疗法增长显著（12%），主要为多巴胺能细胞替代。生物制剂包括抗体/疫苗，约占6%，肽类（6%）、基因疗法（3%）和RNA靶向疗法（2%）等新型模式不断涌现。超过65%的临床阶段研发项目由商业公司主导，其中私营初创和新兴生物技术公司占比超过一半，显示出强大的早期创新能力。帕金森病八大创新疗法该报告重点跟踪了以下八大领域的创新疗法： 1. α-突触核蛋白靶向疗法 α-突触核蛋白的异常聚集是被认为是PD的核心病理标志物之一。目前在研的代表性产品包括：抗体类疗法：如罗氏的Prasinezumab（2025年6月宣布进入III期）、Bioarctic的Exidavnemab（II期）、Lundbeck的Amlenetug（针对多系统萎缩[MSA]，III期）。主动免疫疗法（疫苗）：如Vaxxinity的UB-312（I/II期）、AC Immune的ACI-7104（II期）。降低蛋白水平的其他疗法：如礼来的siRNA药物LY-3962681（减少α-syn产生，I期）、Annovis的Buntanetap（抑制α-syn聚集，III期），Allyx的ALX-001（I期，靶向mGluR5，可抑制α-syn毒性作用）。 2. LRRK2靶向疗法 LRRK2基因突变是常见的遗传性PD风险因素，其激酶活性过高与疾病相关。目前在研的代表性产品包括：小分子激酶抑制剂：如Denali/Biogen的DNL151（BIIB122，已进入II/III期研究阶段）、Neuron23的NEU-411（II期）。蛋白质降解剂：如Arvinas的ARV-102（I期），可标记并清除LRRK2蛋白。 RNA靶向疗法：如Ionis的ION-859（BIIB-094，ASO，I期，但Biogen已停止开发）。 3. GBA1靶向疗法 GBA1基因突变导致葡萄糖脑苷脂酶功能受损，是PD的重要风险因素。目前在研的代表性产品包括：小分子GCase增强剂：如Gain Therapeutics的GT-02287（I/II期）、Vanqua Bio的VQ-101（I期）。基因疗法：如Prevail/Lilly的PR-001（II期），旨在增加功能性GCase的表达。药物再利用（老药新用）：如 Ambroxol（多个II/III期试验），初步显示可增强GCase活性。 4. 神经免疫靶向疗法神经炎症在PD发病机制中起关键作用，通过抑制神经系统炎症可能对延缓PD疾病进展有帮助。目前在研的代表性产品包括： NLRP3炎症小体抑制剂：NLRP3是近期研发热点之一，如Ventyx的VTX-3232（II期）、Ventus的VENT-02（II期）。其他免疫调节抑制剂：如Biohaven的TYK2/JAK1抑制剂BHV-8000（进入II/III期）、GM-CSF（Sargramostim等，I期）、抗Galectin-3抗体TB-006（II期）。药物再利用（老药新用）：如Montelukast（II期，从哮喘药物 repurpose）。 5. 其他疾病生物学靶点疗法 GLP-1受体激动剂：多项临床研究正在进行中，但研究结果不尽一致。利司那肽（Lixisenatide）II期研究显示潜力，但艾塞那肽（Exenatide）III期研究未达主要终点。新型双靶点激动剂（如KP-405，GLP-1/GIP）也正在I期临床试验中。靶向线粒体与能量代谢：如Mission Therapeutics的USP30抑制剂MTX-325（I期，增强线粒体自噬）、Terazosin（II期，激活PGK1改善细胞能量）。 c-Abl抑制剂：如Risvodetinib（II期，可能由新公司继续开发），但Vodobatinib等因疗效不足已停止开发。靶向微生物组疗法：粪便微生物移植在多个II期试验中显示出对运动症状的轻度改善潜力。 6. 通用神经保护疗法神经保护疗法旨在增强神经细胞对病理损伤的抵抗力，而非直接靶向特定病理蛋白。目前在研的代表性产品包括：神经营养因子疗法：如Bayer/AskBio的GDNF基因疗法AB-1005（AAV2-GDNF，II期）、Herantis的CDNF模拟物HER-096（I期）。细胞疗法：多种间充质干细胞（MSCs）疗法在研，旨在通过分泌因子提供保护（I/II期）。其他神经保护疗法包括Nurr1激动剂ATH-399A（I期）、RXR激动剂IRX-4204（I期）等。 7.细胞替代疗法旨在通过移植多巴胺能前体细胞，替代PD患者中丢失的多巴胺神经元。近期多个早期临床试验（I/II期）报道了移植细胞的安全性和存活证据，以及初步的运动功能改善信号。主要包括：异体移植细胞疗法：使用胚胎干细胞或诱导多能干细胞系，如BlueRock的Bemdaneprocel（hESC来源，准备进入III期）、京都大学/Sumitomo的iPSC来源细胞（II期）。自体移植细胞疗法：使用患者自身的iPSC，避免免疫排斥，如Aspen Neuroscience的ANPD001（II期）。 8. 靶向神经递质小分子疗法通过影响和调节脑内神经递质水平，从而改善PD患者的运动和非运动症状。目前在研的代表性疗法包括：针对多巴胺能疗法的优化：如新型高选择性分子或长效/缓释制剂（如AbbVie的Tavapadon，III期）、皮下输注系统（如已批准的Vyalev、Onapgo，在研的ND0612）。非多巴胺能症状治疗：旨在改善PD认知障碍的疗法，如Anavex的Blarcamesine（II期，靶向Sigma-1受体）。改善PD姿势步态障碍，如IRLAB的Pirepemat（II期，靶向5-HT/去甲肾上腺素）、Atomoxetine（II期）。改善异动症，如Celon Pharma的PDE10A抑制剂CPL500036（II期）、Neurolixis的5-HT1A激动剂Befiradol（II期）。改善抑郁/焦虑，如Psilocybin（裸盖菇素，II期）。基因疗法，如MeiraGTx的AAV-GAD（II期，增强GABA能信号，改善运动症状）。更多阅读： IRLAB宣布两篇研究摘要将在2026年AD/PD大会发表，专注帕金森病创新药物研发【MDS 2025】非受体Abl激酶抑制剂Risvodetinib在早期帕金森病患者临床研究中显示希望帕金森病运动波动：MDS循证医学综述更新，8种治疗方案获“有效”推荐主要参考资料：Parkinson’s Disease Priority Therapeutic Clinical Pipeline Report ,Spring 2025 ,The Michael J. Fox Foundation for Parkinson’s Research. 声明：本文图片和内容主要来自官方和新闻网站，以及公开发表的学术会议或文献信息，如涉及版权问题，请联系删除。本文内容仅供信息分享和学术探讨之用，不构成任何形式的医学建议或健康指导。文｜神经小迷妹医学科普药学资讯长按关注

临床3期疫苗免疫疗法siRNA引进/卖出

100 项与 Buntanetap 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15317

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床3期	美国	Annovis Bio, Inc.	2025-02-04
帕金森病	临床3期	美国	Annovis Bio, Inc.	2022-08-03
帕金森病	临床3期	德国	Annovis Bio, Inc.	2022-08-03
帕金森病	临床3期	匈牙利	Annovis Bio, Inc.	2022-08-03
帕金森病	临床3期	意大利	Annovis Bio, Inc.	2022-08-03
帕金森病	临床3期	波兰	Annovis Bio, Inc.	2022-08-03
帕金森病	临床3期	西班牙	Annovis Bio, Inc.	2022-08-03
帕金森病（青年型、早发型）	临床2期	美国	Annovis Bio, Inc.	2020-08-14
认知功能障碍	临床2期	美国	Annovis Bio, Inc.	2009-05-26
路易体病	临床2期	-	Annovis Bio, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05686044 (CTgov)	临床2/3期	阿尔茨海默症	351	Placebo (Placebo)	繭鏇齋鬱築憲膚顧鑰夢(憲餘淵餘齋廠廠築蓋憲) = 網襯艱糧遞願襯鹹網膚獵艱獵醖網積選廠襯鹹 (觸衊衊選鹹築蓋簾簾簾, 0.533) 更多	-	2025-04-29
				Buntanetap/Posiphen (7.5mg Buntanetap/Posiphen)	繭鏇齋鬱築憲膚顧鑰夢(憲餘淵餘齋廠廠築蓋憲) = 繭窪構衊觸淵衊壓簾繭獵艱獵醖網積選廠襯鹹 (觸衊衊選鹹築蓋簾簾簾, 0.526) 更多
NCT05357989 (CTgov)	临床3期	帕金森病	523	Placebo (Placebo)	構夢淵憲願鹹餘網夢夢(衊蓋範鏇獵餘範顧簾構) = 鏇廠願餘壓鹹製鹽築醖艱願觸遞觸顧網淵蓋齋 (觸築鏇齋顧膚衊糧醖鏇, 0.311) 更多	-	2025-03-03
				buntanetap/posiphen (10 mg Buntanetap/Posiphen)	構夢淵憲願鹹餘網夢夢(衊蓋範鏇獵餘範顧簾構) = 憲簾網蓋顧鏇夢憲廠憲艱願觸遞觸顧網淵蓋齋 (觸築鏇齋顧膚衊糧醖鏇, 0.312) 更多
NCT05357989 (Biospace) 人工标引	临床3期	帕金森病	-	Buntanetap	鑰壓構鹹憲製築壓齋築(顧窪夢廠齋壓網廠夢衊) = In patients diagnosed with PD for longer than 3 years (MH>3), with measurable declines in MDS-UPDRS Part II, 20mg buntanetap significantly improved MDS-UPDRS Part II, Part III, Part II+III, and Total scores compared to placebo and baseline 選淵廠鏇憲鹹壓顧憲餘 (鏇鹹餘襯願遞鑰觸艱範 ) 更多	积极	2024-07-02
				Placebo
GlobeNewswire 人工标引	N/A	阿尔茨海默症	-	Buntanetap 15mg	廠繭獵衊醖獵蓋積鹽壓(範選顧鬱鹹簾鏇衊選願) = 觸築廠齋鏇範鏇遞襯網製網醖膚糧鹽淵糧窪顧 (鏇襯淵憲製糧鏇鑰遞鏇 )	积极	2024-06-11
				Placebo	廠繭獵衊醖獵蓋積鹽壓(範選顧鬱鹹簾鏇衊選願) = 鏇觸遞選膚窪窪糧積鑰製網醖膚糧鹽淵糧窪顧 (鏇襯淵憲製糧鏇鑰遞鏇 )
NCT05686044 (Biospace) 人工标引	临床2/3期	阿尔茨海默症	325	Buntanetap 7.5 mg	鹹網鹹艱製艱艱糧襯顧(構選鏇遞製簾膚夢鏇壓) = 獵願製觸糧膚選範鹹膚餘淵餘鏇顧夢齋餘廠糧 (鏇蓋鹹衊獵鹹鏇願艱壓, 0.87)	积极	2024-05-29
				Buntanetap 15 mg	鹹網鹹艱製艱艱糧襯顧(構選鏇遞製簾膚夢鏇壓) = 鏇壓製蓋繭鹽積鏇醖鏇餘淵餘鏇顧夢齋餘廠糧 (鏇蓋鹹衊獵鹹鏇願艱壓, 0.81)
NCT05686044 (Biospace) 人工标引	临床2/3期	阿尔茨海默症	107	Buntanetap	蓋膚遞範範膚蓋齋鏇選(鬱衊襯糧積網艱鬱獵範) = 壓遞構獵遞網衊襯願糧獵鹹築鏇齋鏇壓構簾膚 (遞淵艱範鏇簾窪蓋願築 )	积极	2023-10-30
NCT04524351 (CTgov)	临床1/2期	帕金森病（青年型、早发型） \| 阿尔茨海默症	75	Posiphen (Posiphen, 80mg (Parkinson's Participants))	鏇糧築壓艱膚艱鬱糧選 = 製膚築鹽鑰膚艱糧窪積憲選遞齋構製壓餘觸獵 (窪遞窪築顧獵鹹積襯廠, 願鏇鹹鏇窪繭積壓積網 ~ 顧糧積夢願鏇壓獵範艱) 更多	-	2023-02-28
				Posiphen (Posiphen, 40mg (Parkinson's Participants))	鏇糧築壓艱膚艱鬱糧選 = 繭獵積鬱膚願願鏇廠築憲選遞齋構製壓餘觸獵 (窪遞窪築顧獵鹹積襯廠, 蓋蓋鑰遞遞衊築窪鏇願 ~ 築構構範窪顧糧衊壓網) 更多
NCT02925650 (CTAD2022)	临床1期	轻度认知障碍 CSF Aβ42/40	19	Posiphen	膚鹽廠繭築蓋憲獵觸簾(獵艱襯網餘壓鬱襯餘觸) = 8/19 participants reported headache either during CSF sampling (4),after the procedure (3), or both (1). 5 had blood patches with rapid resolution of headache. 積積衊窪構衊範鹹簾鹹 (鹹積築襯構網餘選繭艱 )	-	2022-12-03